An epidemiological study of equine sarcoid in a population of 4126 donkeys showed that the peak incidence of the disease was 15.2 cases per 100 animal-years and occurred in animals in their fourth year of life. The crude incidence of the disease was 0.6 cases per 100 animal-years. The disease occurred most frequently in younger, male animals during their first five years in the population. The lesions were observed most commonly in the paragenital region. Pre-entry quarantine procedures did not appear to play a significant role in the spread of the disease but there was an indication that close in-contact animals were more likely to have sarcoids than animals in the general population. This suggested that a transmissible agent might have been involved in the aetiopathogenesis or that the animals had encountered some event that had predisposed them to the disease.

Survivors of HL who were AYAs at diagnosis had a mismatch between high need for and low utilization of health services. Providers of healthcare to this population should be made aware of this discrepancy, and the survivors should be encouraged to seek the health services they need.

Background The literature is void of an evidence‐based anticoagulation therapy (ACT) management strategy in the context of thrombocytopenia. We examined the impact of thrombocytopenia on low‐molecular‐weight heparin (LMWH) dosing and incidence of bleeding in children with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) who developed thromboembolism (TE) during therapy according to DFCI ALL protocols. Procedure Patient records from our tertiary care center were reviewed for demographics, details of diagnoses and therapy of ALL/LL and TE diagnoses, platelet counts during ACT, LMWH dosing, and bleeding episodes. Results Thirty‐nine TEs were diagnosed in 33 patients [mean age 9 years (range, 2.5–18); 16 males and 31 with ALL] during the study period. A majority (85%) of patients were diagnosed with TE in the consolidation phase with mean time to TE 5.75 months from ALL/LL diagnosis. All patients received LMWH, and the median duration of ACT was 5.9 months (range, 1–11 months). Platelets were measured weekly. On 29 occasions, platelet nadir was <50 × 109/L, and twice it was < 20 × 109/L. One (3%) patient had major bleeding episode while on ACT. Platelet count at the time of bleeding was 222 × 109/L. Ninety‐two procedures [83 lumbar punctures (LPs), 9 central venous line (CVL) insertion/revision] were completed without bleeding complications. Asparaginase was held temporarily with TE diagnosis in 48% of patients; most (88%) patients completed all scheduled doses as per protocol. Conclusions Ability to administer full‐dose LMWH, expected bleeding rate, and completion of asparaginase doses while on ACT suggest full‐dose ACT is feasible and safe in children with ALL/LL who develop TE during DFCI ALL consortium therapy protocols.